Sobi Returns To Deal-Making With ADC Lymphoma Licensing Pact
Pays $55m Upfront For Rights To Zynlonta
The Swedish rare disease specialist has expanded its hematology franchise by getting the European rights to ADC Therapeutics’ Zynlonta, which has yet to make much impact commercially in the US.
